Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.46
RHHBY's Cash to Debt is ranked higher than
52% of the 1254 Companies
in the Global Biotechnology industry.

( Industry Median: 57.26 vs. RHHBY: 0.46 )
RHHBY' s 10-Year Cash to Debt Range
Min: 0.36   Max: No Debt
Current: 0.46

Equity to Asset 0.29
RHHBY's Equity to Asset is ranked higher than
55% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. RHHBY: 0.29 )
RHHBY' s 10-Year Equity to Asset Range
Min: 0.13   Max: 0.59
Current: 0.29

0.13
0.59
F-Score: 5
Z-Score: 3.63
M-Score: -2.79
WACC vs ROIC
9.08%
39.63%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 34.30
RHHBY's Operating margin (%) is ranked higher than
96% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. RHHBY: 34.30 )
RHHBY' s 10-Year Operating margin (%) Range
Min: 4.53   Max: 33.69
Current: 34.3

4.53
33.69
Net-margin (%) 23.15
RHHBY's Net-margin (%) is ranked higher than
94% of the 1033 Companies
in the Global Biotechnology industry.

( Industry Median: -78.17 vs. RHHBY: 23.15 )
RHHBY' s 10-Year Net-margin (%) Range
Min: -13.67   Max: 30.16
Current: 23.15

-13.67
30.16
ROE (%) 51.81
RHHBY's ROE (%) is ranked higher than
98% of the 1150 Companies
in the Global Biotechnology industry.

( Industry Median: -34.19 vs. RHHBY: 51.81 )
RHHBY' s 10-Year ROE (%) Range
Min: -16.17   Max: 82.24
Current: 51.81

-16.17
82.24
ROA (%) 16.15
RHHBY's ROA (%) is ranked higher than
96% of the 1259 Companies
in the Global Biotechnology industry.

( Industry Median: -27.46 vs. RHHBY: 16.15 )
RHHBY' s 10-Year ROA (%) Range
Min: -5.78   Max: 17.58
Current: 16.15

-5.78
17.58
ROC (Joel Greenblatt) (%) 80.33
RHHBY's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 1232 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. RHHBY: 80.33 )
RHHBY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 6.9   Max: 84.52
Current: 80.33

6.9
84.52
Revenue Growth (3Y)(%) 5.00
RHHBY's Revenue Growth (3Y)(%) is ranked higher than
80% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. RHHBY: 5.00 )
RHHBY' s 10-Year Revenue Growth (3Y)(%) Range
Min: -2.3   Max: 391.7
Current: 5

-2.3
391.7
EBITDA Growth (3Y)(%) 3.10
RHHBY's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 692 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. RHHBY: 3.10 )
RHHBY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -5.1   Max: 280
Current: 3.1

-5.1
280
EPS Growth (3Y)(%) -0.50
RHHBY's EPS Growth (3Y)(%) is ranked higher than
80% of the 699 Companies
in the Global Biotechnology industry.

( Industry Median: -5.90 vs. RHHBY: -0.50 )
RHHBY' s 10-Year EPS Growth (3Y)(%) Range
Min: -3.8   Max: 341.1
Current: -0.5

-3.8
341.1
» RHHBY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

RHHBY Guru Trades in Q1 2014

Ken Fisher 1,803,070 sh (+99%)
Bill Frels 2,138,396 sh (+5.45%)
» More
Q2 2014

RHHBY Guru Trades in Q2 2014

Bill Frels 2,184,810 sh (+2.17%)
Ken Fisher 1,813,443 sh (-49.71%)
» More
Q3 2014

RHHBY Guru Trades in Q3 2014

Bill Frels 2,391,096 sh (+9.44%)
Ken Fisher 1,891,406 sh (+4.3%)
» More
Q4 2014

RHHBY Guru Trades in Q4 2014

Ken Fisher 2,823,025 sh (+49.26%)
» More
» Details

Insider Trades

Latest Guru Trades with RHHBY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2014-12-31 Add 49.26%0.07%$34.16 - $37.92 $ 33.76-7%2823025
Ken Fisher 2014-06-30 Reduce -49.71%0.07%$35.42 - $38.07 $ 33.76-8%1813443
Ken Fisher 2014-03-31 Add 99%0.07%$18.14 - $38.17 $ 33.7614%1803070
Tweedy Browne 2013-06-30 Sold Out $28.92 - $32.98 $ 33.769%0
Ken Fisher 2013-03-31 Add 634.57%0.12%$25.25 - $29.3 $ 33.7622%897861
Tweedy Browne 2012-09-30 Reduce -24.31%0.03%$20.95 - $24.07 $ 33.7651%62164
Vanguard Health Care Fund 2012-06-30 Add 543.36%2.96%$19.47 - $23.14 $ 33.7660%4273977
Ken Fisher 2012-06-30 Reduce -24.26%0.01%$19.47 - $23.14 $ 33.7660%154713
Ken Fisher 2012-03-31 Reduce -98.02%1.27%$21.55 - $22.17 $ 33.7668%204276
Tweedy Browne 2012-03-31 Reduce -22.19%0.04%$21.55 - $22.17 $ 33.7668%82130
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 23.40
RHHBY's P/E(ttm) is ranked higher than
97% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 23.40 )
RHHBY' s 10-Year P/E(ttm) Range
Min: 13.05   Max: 36.39
Current: 23.4

13.05
36.39
Forward P/E 15.53
RHHBY's Forward P/E is ranked higher than
97% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 15.53 )
N/A
PE(NRI) 23.40
RHHBY's PE(NRI) is ranked higher than
97% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 23.40 )
RHHBY' s 10-Year PE(NRI) Range
Min: 13.05   Max: 44.62
Current: 23.4

13.05
44.62
P/B 9.96
RHHBY's P/B is ranked higher than
66% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 6.43 vs. RHHBY: 9.96 )
RHHBY' s 10-Year P/B Range
Min: 2.64   Max: 17.39
Current: 9.96

2.64
17.39
P/S 4.37
RHHBY's P/S is ranked higher than
91% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 28.83 vs. RHHBY: 4.37 )
RHHBY' s 10-Year P/S Range
Min: 2.38   Max: 6.45
Current: 4.37

2.38
6.45
PFCF 17.31
RHHBY's PFCF is ranked higher than
97% of the 1349 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 17.31 )
RHHBY' s 10-Year PFCF Range
Min: 8.6   Max: 39.65
Current: 17.31

8.6
39.65
POCF 13.69
RHHBY's POCF is ranked higher than
97% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 13.69 )
RHHBY' s 10-Year POCF Range
Min: 6.98   Max: 25.96
Current: 13.69

6.98
25.96
EV-to-EBIT 16.38
RHHBY's EV-to-EBIT is ranked higher than
97% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 16.38 )
RHHBY' s 10-Year EV-to-EBIT Range
Min: 7.9   Max: 32
Current: 16.38

7.9
32
PEG 6.69
RHHBY's PEG is ranked higher than
96% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 6.69 )
RHHBY' s 10-Year PEG Range
Min: 0.3   Max: 4.52
Current: 6.69

0.3
4.52
Shiller P/E 22.57
RHHBY's Shiller P/E is ranked higher than
99% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 22.57 )
RHHBY' s 10-Year Shiller P/E Range
Min: 13.35   Max: 110.34
Current: 22.57

13.35
110.34
Current Ratio 1.35
RHHBY's Current Ratio is ranked higher than
55% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. RHHBY: 1.35 )
RHHBY' s 10-Year Current Ratio Range
Min: 1.35   Max: 3.75
Current: 1.35

1.35
3.75
Quick Ratio 1.01
RHHBY's Quick Ratio is ranked higher than
54% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. RHHBY: 1.01 )
RHHBY' s 10-Year Quick Ratio Range
Min: 1.01   Max: 3.22
Current: 1.01

1.01
3.22
Days Inventory 201.61
RHHBY's Days Inventory is ranked higher than
82% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 201.61 )
RHHBY' s 10-Year Days Inventory Range
Min: 109.1   Max: 245.45
Current: 201.61

109.1
245.45
Days Sales Outstanding 70.73
RHHBY's Days Sales Outstanding is ranked higher than
80% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 115.05 vs. RHHBY: 70.73 )
RHHBY' s 10-Year Days Sales Outstanding Range
Min: 65.9   Max: 86.72
Current: 70.73

65.9
86.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.28
RHHBY's Dividend Yield is ranked higher than
91% of the 195 Companies
in the Global Biotechnology industry.

( Industry Median: 1.13 vs. RHHBY: 3.28 )
RHHBY' s 10-Year Dividend Yield Range
Min: 0.74   Max: 4.55
Current: 3.28

0.74
4.55
Dividend Payout 0.73
RHHBY's Dividend Payout is ranked higher than
95% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 0.73 )
RHHBY' s 10-Year Dividend Payout Range
Min: 0.21   Max: 0.59
Current: 0.73

0.21
0.59
Dividend growth (3y) 5.70
RHHBY's Dividend growth (3y) is ranked higher than
82% of the 87 Companies
in the Global Biotechnology industry.

( Industry Median: 11.10 vs. RHHBY: 5.70 )
RHHBY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 27.3
Current: 5.7

0
27.3
Yield on cost (5-Year) 2.85
RHHBY's Yield on cost (5-Year) is ranked higher than
78% of the 200 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. RHHBY: 2.85 )
RHHBY' s 10-Year Yield on cost (5-Year) Range
Min: 0.66   Max: 4.05
Current: 2.85

0.66
4.05
Share Buyback Rate -0.50
RHHBY's Share Buyback Rate is ranked higher than
93% of the 867 Companies
in the Global Biotechnology industry.

( Industry Median: -10.40 vs. RHHBY: -0.50 )
RHHBY' s 10-Year Share Buyback Rate Range
Min: 78.7   Max: -0.8
Current: -0.5

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.62
RHHBY's Price/DCF (Projected) is ranked higher than
98% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. RHHBY: 1.62 )
RHHBY' s 10-Year Price/DCF (Projected) Range
Min: 1.25   Max: 7.13
Current: 1.62

1.25
7.13
Price/Median PS Value 1.12
RHHBY's Price/Median PS Value is ranked higher than
83% of the 1351 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. RHHBY: 1.12 )
RHHBY' s 10-Year Price/Median PS Value Range
Min: 0.66   Max: 1.31
Current: 1.12

0.66
1.31
Earnings Yield (Greenblatt) 6.10
RHHBY's Earnings Yield (Greenblatt) is ranked higher than
96% of the 1235 Companies
in the Global Biotechnology industry.

( Industry Median: -5.70 vs. RHHBY: 6.10 )
RHHBY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 3.1   Max: 12.7
Current: 6.1

3.1
12.7
Forward Rate of Return (Yacktman) 9.04
RHHBY's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 163 Companies
in the Global Biotechnology industry.

( Industry Median: 14.52 vs. RHHBY: 9.04 )
RHHBY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 2.2   Max: 79.2
Current: 9.04

2.2
79.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:GSK, JNJ, PFE, NVS, ABT » details
Traded in other countries:RO.Switzerland, ROG.Switzerland, RHO6.Germany, RHO5.Germany, RHO.Germany, 0QQ6.UK, 0QOK.UK, ROG N.Mexico,
Roche Holding AG Roche Holding AG was founded in 1896. It is a pharmaceutical and diagnostic company. It researches and produces medicines in oncology, infectious diseases, immunology, metabolism and neuroscience. It has more than 60 new molecular entities in its pipeline. The Company's business is organized into two divisions: Pharmaceuticals and diagnostics. Pharmaceuticals division is divided into two sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. Diagnostics division includes five business areas: Applied Science, Molecular Diagnostics, Professional Diagnostics, Tissue Diagnosis and Diabetes Care.
» More Articles for RHHBY

Headlines

Articles On GuruFocus.com
Pharmaceuticals Sector To See High Voltage Action in 2015 Jan 23 2015 
Roche In Expansion Mode Jan 19 2015 
Why Organovo is A Safe Buy? Dec 18 2014 
Is Organovo A Safe Buy? Dec 08 2014 
The Top 5 European Stocks Held During Q3 Nov 25 2014 
Tweedy Browne Global Reports its Top Five Picks of Q3 Oct 21 2014 
Widely Held Guru Stocks Trading In Europe Sep 22 2014 
Dodge & Cox Second Quarter 2014 Commentary Jul 23 2014 
Tweedy Browne Global Reports Their Second Quarter Portfolio Jul 18 2014 
Signature Select Canadian Fund's Top Holdings Jul 02 2014 

More From Other Websites
Roche Misses on Earnings in 2014, Beats on Revenues - Analyst Blog Jan 29 2015
Roche and Qualcomm Collaborate to Innovate Remote Patient Monitoring Jan 29 2015
AstraZeneca's Regulatory Filing for Lesinurad Accepted - Analyst Blog Jan 26 2015
Roche receives FDA clearance for next generation cobas MRSA/SA Test Jan 26 2015
Putting the spotlight on Illumina Jan 23 2015
Curis Up on Immuno-Oncology Agreement with Aurigene - Analyst Blog Jan 22 2015
Investment Bets On Antibiotics To Help Invigorate Investor Portfolios Jan 21 2015
Ventana seeks FDA premarket approval for ALK IHC companion diagnostic to benefit lung cancer... Jan 21 2015
Evotec Signs New Deal for Addictive Disorder Therapies - Analyst Blog Jan 20 2015
Roche to Acquire French Biotechnology Company Trophos - Analyst Blog Jan 19 2015
Amgen (AMGN) Reveals Mixed Results from Vectibix Studies - Analyst Blog Jan 16 2015
Watchmakers Caught In The #Francogeddon Storm Jan 16 2015
A First in North America: CDL Laboratories acquire the latest technology in laboratory analysis from... Jan 15 2015
Own Swiss ADRs? It's better to be lucky than good Jan 15 2015
Swiss ADRs Rise as Franc Surges Jan 15 2015
Why Transparency And Data Sharing In Clinical Trials Matters Jan 15 2015
European Stocks Trade Mixed After Switzerland Scraps Euro Exchange Cap Jan 15 2015
Roche to Acquire Up to 56% Interest in Foundation Medicine - Analyst Blog Jan 14 2015
AstraZeneca Inks Immuno-Oncology Agreement with Omnis - Analyst Blog Jan 14 2015
European Stocks Rise as Retailer Gains Offset Slumping Energy Stocks Jan 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK